<p>，/PRNewswire/ -- 上海 StairMed 科技有限公司（&#34;StairMed&#34;或&#34;公司&#34;）最近宣佈完成一輪總額為 5 億元人民幣的戰略融資。該輪融資由阿里巴巴主導，現有股東包括騰訊、Fountainbridge Capital、OrbiMed、Oriza Seed、啓明創投、Lilly Asia Ventures (LAV) 和 Source Code Capital 等也積極參與。Springhill Fund 擔任獨家財務顧問。這輪融資使 StairMed 在過去一年內的總融資額超過了 11 億元人民幣。這一輪融資也標誌着阿里巴巴和騰訊在腦機接口領域的罕見聯合投資。</p>
<p>繼續閲讀</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p><strong>加速臨牀里程碑：腦機接口系統的多中心試驗定於 2026 年中期進行，神經調節管線推進</strong></p>
<p>隨着這輪融資的完成，StairMed 計劃加速其技術平台和臨牀項目的發展，基於去年完成的三例成功的腦機接口（BMI）系統臨牀植入。在 2026 年初，StairMed 利用其自主研發的手術機器人完成了 256 通道無線高通量侵入式 BMI 系統（WRS02）的植入，作為註冊過程的一部分，併成功驗證了腦控交互功能。這個里程碑代表了 StairMed 的重大技術進步，並標誌着中國首個 256 通道侵入式 BMI 的臨牀試驗。該系統目前是中國唯一獲得國家藥品監督管理局（NMPA）創新醫療器械綠色通道的侵入式 BMI。</p>
<p>展望未來，StairMed 計劃啓動其臨牀開發項目的下一階段。大規模的多中心註冊臨牀試驗預計將在 2026 年中期開始，目標是在一年內招募並植入約 40 名患者。到 2026 年底，StairMed 的累計植入患者數量預計將達到數十人，代表着侵入式 BMI 技術臨牀發展的重要一步。</p>
<p>與其腦控產品開發並行，StairMed 正在擴展其神經調節產品組合。</p>
<p>憑藉其超靈活的微電極技術，StairMed 開發了一種閉環、超低損傷的深腦刺激（DBS）系統，其性能在微觀尺寸和靈活性等核心指標上與國際領先系統相當。該系統已在四名患者中植入，作為臨牀研究的一部分，驗證了其治療潛力。公司計劃在 2027 年啓動該系統的正式臨牀試驗，目標是為帕金森病、癲癇和其他神經系統疾病的患者提供變革性的治療選擇，進一步鞏固 StairMed 在全球 BMI 領域的地位。</p>
<p><strong>與技術領袖的戰略對接推動下一代人機交互</strong></p>
<p>BMI 行業的快速發展越來越受到計算和人工智能（AI）進步的推動。</p>
<p>StairMed 創始人李雪表示：&#34;我們感謝現有股東自公司早期以來的持續支持，特別是作為核心產業投資者的騰訊。我們也歡迎阿里巴巴和 SDIC Unity Capital 參與這一輪融資。&#34;李指出，領先互聯網和科技公司深度參與的戰略重要性，&#34;BMI 不僅是一項新興的醫療技術，也是生命科學與信息技術的交匯點。這些行業領袖在多模態大模型、計算基礎設施、智能硬件和生態系統開發方面的深厚專業知識與 StairMed 在 BMI 硬件和臨牀轉化方面的優勢緊密契合。這種合作將使我們能夠共同開發下一代智能 BMI 系統和前沿應用生態系統。這不僅是對醫療創新的投資，更是對人機交互長期潛力的戰略押注。&#34;</p>
<p><strong>關於 StairMed</strong></p>
<p>上海 StairMed 科技有限公司成立於 2021 年，是微創植入式腦機接口（BMI）領域的先驅。</p>
<p>StairMed 開發了電極、系統、算法和手術機器人等專有技術。公司創造了寬度僅為人類頭髮百分之一的超靈活電極和世界上最小的無線 BMI 植入物。2025 年，公司完成了中國首個侵入式 BMI 的前瞻性臨牀試驗，其產品已獲得國家藥品監督管理局創新醫療器械綠色通道的准入。</p>
<p>StairMed 專注於腦控和神經調節兩個主要領域，為運動障礙和神經疾病患者提供創新療法。其長期使命是實現腦與機器智能的融合。</p>
<p>來源：StairMed</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9Q04yNTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIwMjQxUFJfTkVXU19VU1BSX19fX19DTjI1ODAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9Q04yNTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIwMjQxUFJfTkVXU19VU1BSX19fX19DTjI1ODAy"/></p>

騰訊控股(ADS)

騰訊控股(ADR)

2 倍做多阿里巴巴 ETF - KraneShares

2 倍做多 BABA ETF - GraniteShares

<p>上海斯泰爾醫療科技有限公司在阿里巴巴的主導下，成功獲得 5 億人民幣的戰略融資，騰訊及其他投資者也參與了此次融資。這筆資金將加速其腦機接口（BMI）技術的發展，此前已成功進行臨牀植入。斯泰爾計劃在 2026 年中期啓動大規模臨牀試驗，並擴展其神經調節產品組合。該公司旨在通過與科技領袖的合作，增強人機交互，力爭成為 BMI 領域的關鍵參與者</p>

<p>, /PRNewswire/ -- Shanghai StairMed Technology Co., Ltd. (&#34;StairMed&#34; or &#34;the Company&#34;) recently announced the closing of a strategic financing round totaling RMB 500 million. The round was led by Alibaba, with strong continued participation from existing shareholders including Tencent, Fountainbridge Capital, OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Ventures (LAV), and Source Code Capital, etc. Springhill Fund served as the exclusive financial advisor. This latest round brings StairMed's total funding raised in the past year to over RMB 1.1 billion. This round also marks a rare joint investment by Alibaba and Tencent in the brain-machine interface sector.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- 上海 StairMed 科技有限公司（&#34;StairMed&#34;或&#34;公司&#34;）最近宣佈完成一輪總額為 5 億元人民幣的戰略融資。該輪融資由阿里巴巴主導，現有股東包括騰訊、Fountainbridge Capital、OrbiMed、Oriza Seed、啓明創投、Lilly Asia Ventures (LAV) 和 Source Code Capital 等也積極參與。Springhill Fund 擔任獨家財務顧問。這輪融資使 StairMed 在過去一年內的總融資額超過了 11 億元人民幣。這一輪融資也標誌着阿里巴巴和騰訊在腦機接口領域的罕見聯合投資。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>繼續閲讀</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p><strong>Accelerating Clinical Milestones: Multi-Center Trials for BMI Systems Set for Mid-2026, Neuromodulation Pipeline Advances</strong></p>
<div class="lb-trans"><p><strong>加速臨牀里程碑：腦機接口系統的多中心試驗定於 2026 年中期進行，神經調節管線推進</strong></p>
</div><p>With the closing of this financing round, StairMed plans to accelerate development of its technology platform and clinical programs, building on three successful clinical implants of its brain-machine interface (BMI) system completed last year. In early 2026, StairMed used its proprietary surgical robot to complete implantation of its 256-channel wireless high-throughput invasive BMI system (WRS02) as part of the registration process and successfully validated brain-controlled interaction functions. This milestone represents a significant technological advancement for StairMed and marks the first clinical trial of a 256-channel invasive BMI in China. The system is currently the only invasive BMI in China to receive access to the National Medical Products Administration (NMPA) Green Channel for Innovative Medical Devices.</p>
<div class="lb-trans"><p>隨着這輪融資的完成，StairMed 計劃加速其技術平台和臨牀項目的發展，基於去年完成的三例成功的腦機接口（BMI）系統臨牀植入。在 2026 年初，StairMed 利用其自主研發的手術機器人完成了 256 通道無線高通量侵入式 BMI 系統（WRS02）的植入，作為註冊過程的一部分，併成功驗證了腦控交互功能。這個里程碑代表了 StairMed 的重大技術進步，並標誌着中國首個 256 通道侵入式 BMI 的臨牀試驗。該系統目前是中國唯一獲得國家藥品監督管理局（NMPA）創新醫療器械綠色通道的侵入式 BMI。</p>
</div><p>Looking ahead, StairMed plans to initiate the next phase of its clinical development program. Large-scale, multi-center registration clinical trials are on track to begin in mid-2026, with the goal of enrolling and implanting approximately 40 patients within the year. By the end of 2026, StairMed's cumulative number of patients implanted is expected to reach several dozen, representing a significant step in the clinical development of invasive BMI technology.</p>
<div class="lb-trans"><p>展望未來，StairMed 計劃啓動其臨牀開發項目的下一階段。大規模的多中心註冊臨牀試驗預計將在 2026 年中期開始，目標是在一年內招募並植入約 40 名患者。到 2026 年底，StairMed 的累計植入患者數量預計將達到數十人，代表着侵入式 BMI 技術臨牀發展的重要一步。</p>
</div><p>In parallel with its brain-controlled product development, StairMed is expanding its neuromodulation portfolio.</p>
<div class="lb-trans"><p>與其腦控產品開發並行，StairMed 正在擴展其神經調節產品組合。</p>
</div><p>Drawing on its ultra-flexible microelectrode technology, StairMed has developed a closed-loop, ultra-low-damage deep brain stimulation (DBS) system, with performance comparable to leading international systems on core metrics such as microscale dimensions and flexibility. It has already been implanted in four patients as part of clinical research, validating its therapeutic potential. The Company plans to initiate formal clinical trials for this system in 2027, targeting transformative treatment options for patients with Parkinson's disease, epilepsy, and other neurological disorders, and further strengthening StairMed's position in the global BMI landscape.</p>
<div class="lb-trans"><p>憑藉其超靈活的微電極技術，StairMed 開發了一種閉環、超低損傷的深腦刺激（DBS）系統，其性能在微觀尺寸和靈活性等核心指標上與國際領先系統相當。該系統已在四名患者中植入，作為臨牀研究的一部分，驗證了其治療潛力。公司計劃在 2027 年啓動該系統的正式臨牀試驗，目標是為帕金森病、癲癇和其他神經系統疾病的患者提供變革性的治療選擇，進一步鞏固 StairMed 在全球 BMI 領域的地位。</p>
</div><p><strong>Strategic Alignment with Technology Leaders Drives Next-Generation Human-Machine Interaction</strong></p>
<div class="lb-trans"><p><strong>與技術領袖的戰略對接推動下一代人機交互</strong></p>
</div><p>The rapid evolution of the BMI industry is increasingly driven by advances in computing and artificial intelligence (AI).</p>
<div class="lb-trans"><p>BMI 行業的快速發展越來越受到計算和人工智能（AI）進步的推動。</p>
</div><p>Li Xue, founder of StairMed, commented, &#34;We are grateful to our existing shareholders for their continued support since our early days, particularly Tencent as a core industrial investor. We also welcome Alibaba and SDIC Unity Capital to this round.&#34; Li noted the strategic importance of deep involvement from leading internet and technology companies, &#34;BMI is not only an emerging medical technology, but also a point of convergence between life sciences and information technology. The deep expertise of these industry leaders in multi-modal large models, computing infrastructure, intelligent hardware, and ecosystem development aligns closely with StairMed's strengths in BMI hardware and clinical translation. This partnership will enable us to co-develop next-generation intelligent BMI systems and cutting-edge application ecosystems. This is more than an investment in medical innovation—it is a strategic bet on the long-term potential of human-machine interaction.&#34;</p>
<div class="lb-trans"><p>StairMed 創始人李雪表示：&#34;我們感謝現有股東自公司早期以來的持續支持，特別是作為核心產業投資者的騰訊。我們也歡迎阿里巴巴和 SDIC Unity Capital 參與這一輪融資。&#34;李指出，領先互聯網和科技公司深度參與的戰略重要性，&#34;BMI 不僅是一項新興的醫療技術，也是生命科學與信息技術的交匯點。這些行業領袖在多模態大模型、計算基礎設施、智能硬件和生態系統開發方面的深厚專業知識與 StairMed 在 BMI 硬件和臨牀轉化方面的優勢緊密契合。這種合作將使我們能夠共同開發下一代智能 BMI 系統和前沿應用生態系統。這不僅是對醫療創新的投資，更是對人機交互長期潛力的戰略押注。&#34;</p>
</div><p><strong>About StairMed</strong></p>
<div class="lb-trans"><p><strong>關於 StairMed</strong></p>
</div><p>Shanghai StairMed Technology Co., Ltd., founded in 2021, is a pioneer in the field of minimally invasive implantable brain-machine interfaces (BMI).</p>
<div class="lb-trans"><p>上海 StairMed 科技有限公司成立於 2021 年，是微創植入式腦機接口（BMI）領域的先驅。</p>
</div><p>StairMed has developed proprietary technologies for electrodes, systems, algorithms, and surgical robotics. The Company has created ultra-flexible electrodes as fine as one-hundredth the width of a human hair and the world's smallest wireless BMI implant. In 2025, it completed China's first prospective clinical trial for an invasive BMI, and its product has been granted access to the NMPA Green Channel for Innovative Medical Devices.</p>
<div class="lb-trans"><p>StairMed 開發了電極、系統、算法和手術機器人等專有技術。公司創造了寬度僅為人類頭髮百分之一的超靈活電極和世界上最小的無線 BMI 植入物。2025 年，公司完成了中國首個侵入式 BMI 的前瞻性臨牀試驗，其產品已獲得國家藥品監督管理局創新醫療器械綠色通道的准入。</p>
</div><p>StairMed focuses on two primary areas—brain control and neuromodulation—to deliver innovative therapies for patients with movement disorders and neurological diseases. Its long-term mission is to achieve the integration of brain and machine intelligence.</p>
<div class="lb-trans"><p>StairMed 專注於腦控和神經調節兩個主要領域，為運動障礙和神經疾病患者提供創新療法。其長期使命是實現腦與機器智能的融合。</p>
</div><p>SOURCE StairMed</p>
<div class="lb-trans"><p>來源：StairMed</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9Q04yNTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIwMjQxUFJfTkVXU19VU1BSX19fX19DTjI1ODAy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN25802&amp;Transmission_Id=202604020241PR_NEWS_USPR_____CN25802&amp;DateId=20260402"/></p>

02:41 ETStairMed Secures RMB 500 Million Financing Led by Alibaba, Joined by Tencent

- 上海 StairMed 技術有限公司完成 5 億人民幣的戰略融資，主要投資方為阿里巴巴和騰訊等。  
- 融資後，StairMed 計劃加速其腦機接口技術平台的開發，並將在 2026 年中開始多中心臨牀試驗。  
- 公司預計到 2026 年底，植入患者人數將達數十名，推動侵入性腦機接口技術的臨牀進展。

02:41 ETStairMed 獲得阿里巴巴領投、騰訊參投的 5 億元人民幣融資